iBreastExam · Now available in Malaysia
Early detection saves lives.
Breast cancer is the number one cancer killer of Malaysian women. iBreastExam makes early detection possible — painless, radiation-free, and results in just 10 minutes.
Breast health awareness
10 minutes can save your life.
Breast cancer was the most common cancer in women in 157 out of 185 countries in 2022. Deborah Henry explores how early screening empowers us all — because the stats don't lie.
Featuring Deborah Henry
What is iBreastExam?
A smarter way to screen.
87.5%
five-year survival rate when breast cancer is caught at Stage I. At Stage IV: 23.3%.
iBreastExam is a handheld, FDA-cleared breast screening device that uses tactile pressure sensors to detect differences in tissue stiffness — an early sign of breast lesions. Painless, radiation-free, and delivers results in 10 minutes.
Breast cancer is the NUMBER ONE cancer killer of Malaysian women, accounting for 17.6% of all new cancer cases in 2017–2021. 1 in 23 women in Malaysia is at risk.
No Direct Human Touch
Tactile pressure sensors map breast tissue without direct contact — preserving comfort and dignity at every step.
Radiation Free
Unlike mammograms, iBreastExam emits zero radiation, making it safe for repeated use at any age.
Results in 10 Minutes
Instant output on a paired smartphone — no waiting, no labs, no anxiety-filled days.
Non-Invasive & Painless
The device rests lightly on the skin. Patients consistently describe the sensation as comfortable.
Detects Breast Lesions
Clinically validated to detect differences in breast tissue stiffness — an early indicator of lesions.
Quick & Accessible
Designed for outreach, clinics, and community programmes. No large infrastructure required.
Simple. Safe. Fast.
How it works
Four straightforward steps from arrival to results — the whole experience takes around 10 minutes.
4 steps • ~10 minutes
01
Any Adult Woman Can Screen
All adult women are encouraged to take an iBreastExam. No referral needed. No prior symptoms required. Screening is for everyone — prevention starts before problems appear.
02
Light & Comfortable on the Skin
The device sits gently on the breast tissue. There is no compression, no radiation, and no discomfort. Most women describe the sensation as a light, calm pressure — nothing more.
03
Zero Pain. Zero Radiation.
iBreastExam uses tactile sensors, not radiation. The screening is completely painless and safe for repeated use — no exposure risks, no recovery time.
04
Results in 10 Minutes
The scan is transmitted instantly to a paired smartphone. A trained healthcare professional reviews the output with you on the spot. No labs. No waiting. Just clarity.
Trusted globally
The case for early screening
The evidence is clear. Catching breast cancer early dramatically improves outcomes — and iBreastExam makes early detection accessible to every woman.
1,000,000+
Women Examined Worldwide
Award-winning technology backed by multiple peer-reviewed publications and global health equity programmes.
87.5%
Stage I Survival Rate
Breast cancer caught at Stage I carries an 87.5% five-year survival rate. At Stage IV it falls to 23.3%.
1 in 23
Malaysian Women at Risk
Breast cancer is the NUMBER ONE cancer killer of Malaysian women — 17.6% of all new diagnoses in 2017–2021.
World Health Organization
The World Bank
FDA U.S. Food & Drug Administration
Pennsylvania Dept. of Health
ACOG
Early detection for all
Whether you are a woman seeking peace of mind or a healthcare organisation ready to expand access to screening — iBreastExam is designed for you.
Questions?
For individuals
Find an iBreastExam screening near you
Contact us to locate a certified iBreastExam provider in your area. Quick, painless, and just 10 minutes. Early detection is the best protection.
For clinics & organisations
Enquire about partnership
Bring iBreastExam to your community
Partner with mobecomm.health to deploy iBreastExam in your clinic, outreach programme, or corporate wellness initiative. Scalable, low-infrastructure, clinically validated.
Download our English pamphlet for full clinical information.